Interestingly, in animal models of Parkinson’s disease (PD) and Alzheimer’s disease (AD), administration of GLP-1 receptor agonists may decrease the amyloid load, slow down dopaminergic degeneration, and improve motor and cognitive functions such as learning and memory [8,12,13,14,15,16,17,18,19,20,21,22,23]. The gene discussed is GLP1R; the disease is early-onset autosomal dominant Alzheimer disease.